BioAge Labs, Inc. (NASDAQ:BIOA) Receives Consensus Rating of “Moderate Buy” from Analysts

BioAge Labs, Inc. (NASDAQ:BIOA) has been given a consensus recommendation of “Moderate Buy” by the seven brokerages that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $43.50.

Several analysts have recently weighed in on the company. Oppenheimer assumed coverage on BioAge Labs in a report on Wednesday, February 25th. They set an “outperform” rating and a $60.00 price target on the stock. Roth Mkm initiated coverage on BioAge Labs in a research note on Wednesday, May 27th. They issued a “buy” rating and a $36.00 price objective on the stock. Citigroup lifted their price objective on BioAge Labs from $15.00 to $52.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a research note on Friday, April 24th. Finally, BTIG Research initiated coverage on BioAge Labs in a research note on Wednesday, May 13th. They issued a “buy” rating and a $40.00 price objective on the stock.

Hedge Funds Weigh In On BioAge Labs

Hedge funds and other institutional investors have recently made changes to their positions in the stock. GSA Capital Partners LLP acquired a new position in shares of BioAge Labs in the third quarter worth approximately $181,000. R Squared Ltd acquired a new position in BioAge Labs in the third quarter valued at approximately $154,000. Nano Cap New Millennium Growth Fund L P acquired a new position in BioAge Labs in the fourth quarter valued at approximately $1,058,000. Walleye Capital LLC lifted its stake in BioAge Labs by 12.5% in the first quarter. Walleye Capital LLC now owns 151,674 shares of the company’s stock valued at $2,653,000 after buying an additional 16,879 shares during the period. Finally, Militia Capital Management LLC acquired a new position in BioAge Labs in the first quarter valued at approximately $565,000.

BioAge Labs Trading Down 3.8%

NASDAQ:BIOA opened at $16.54 on Friday. The stock has a market cap of $735.20 million, a P/E ratio of -6.89 and a beta of 0.94. The stock’s 50-day moving average is $17.34 and its 200-day moving average is $16.58. BioAge Labs has a 1-year low of $3.93 and a 1-year high of $24.00.

BioAge Labs (NASDAQ:BIOA) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.19. The company had revenue of $2.77 million for the quarter. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%. As a group, equities analysts forecast that BioAge Labs will post -2.68 EPS for the current year.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.